Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

Trial Profile

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs PBF 999 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov
    • 06 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top